MedTrace Logo

Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis

NCT02039531 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2015-05-05

No results posted yet for this study

Summary

HYPOTHESIS:

The application of plasma rich in growth factors (PRGF) will improve the quality of life and functional capacity of patients diagnosed with knee osteoarthritis, providing better functional results than conventional treatment with viscosupplementation.

OPERATING ASSUMPTIONS

Following the initial administration of three doses of PRGF interspersed every 15 days, applied via intraarticular, patients will present an improvement in functional test (WOMAC and Lequesne scales) of 15% or more after 6 and 12 months compared to the control group with patients treated with hyaluronic acid.

Conditions

Interventions

BIOLOGICAL

Plasma rich in growth factors

DRUG

Hyaluronic Acid

Sponsors & Collaborators

  • Funds for independent clinical research by the spanish ministry of health

    collaborator UNKNOWN

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias

    lead OTHER

Principal Investigators

  • Victor Vaquerizo, MD,PhD · Hospital Universitario Principe de Asturias

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-02-28
Completion
2015-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02039531 on ClinicalTrials.gov